Climate Change Data

Island Pharmaceuticals Limited

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Social Outcomes (Combating Dengue Fever)
  • Patient Safety
  • Board Diversity
  • Business Ethics

Social Achievements

  • Development of ISLA-101 to combat dengue fever, a priority disease affecting millions.
  • Prioritizes patient safety in clinical trials, leveraging existing safety data of repurposed drug.

Governance Achievements

  • Development of a Diversity Policy.
  • Commitment to the highest ethical standards and compliance with anti-bribery and corruption laws.
  • Establishment of a Remuneration and Nomination Committee.

Climate Goals & Targets

Long-term Goals:
  • Identify lead molecules from research collaborations.
Medium-term Goals:
  • Screen, enroll, and dose subjects in the PEACH trial.
  • Advance through PEACH cohorts and obtain trial readout.
Short-term Goals:
  • Commence the Single Ascending Dose study for ISLA-101.
  • Obtain readouts from the Single Ascending Dose study.

Environmental Challenges

  • Securing IND clearance for ISLA-101 program (Clinical Hold)
  • Additional capital requirements for R&D activities.
  • Intellectual property challenges and potential infringement of third-party IP.
  • Inherent risks in research and development, including potential for product ineffectiveness or unsafety.
  • Regulatory approvals process.
Mitigation Strategies
  • Collaboration with the FDA to resolve IND issues and obtain clearance.
  • Continuous evaluation of R&D data for new uses and partnering opportunities.
  • Strengthening of the team with regulatory and pharmacokinetics expertise.
  • Leveraging pre-existing clinical data for ISLA-101 to expedite clinical trials.
  • Selection of highly credentialed clinical trial partners.

Supply Chain Management

Supplier Audits: Not disclosed

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: SASB

Third-party Assurance: Not disclosed

Sustainable Products & Innovation

  • ISLA-101